SJF-0628

mut. BRAF sel. heterobifunctional degrader

efficacy in xenograft at 50 mg/kg IP BID

VHL-based degrader from vemurafenib

Nat. Comm., Feb. 10, 2021

Yale University, New Haven, CT

13. The Yale BRAF-targeting PROTAC SJF-0628 is a VHL-based heterobifunctional degrader with in vivo activity in a xenograft model (50 mg/kg BID IP). Though mutant BRAF is a well-validated…


 this content is exclusive to
Premium members

Unlock this content with a Premium membership to read it now.